Patent ID: 7759398

Claim:
A method for treating type II diabetes, said method comprising administering to a mammalian patient with type II diabetes an effective amount of cysteamine, or a salt thereof, wherein the effective amount of cysteamine, or salt thereof, is about 0.1 mg to about 400 mg per kilogram of body weight daily; and wherein the cysteamine, or salt thereof, is encapsulated in a host inclusion compound selected from the group consisting of: proteins; crown ethers; polyoxyalkylenes; polysiloxanes; zeolites; cholestyramine; colestipol; colesevelam; colestimide; sevelamer; cellulose derivatives; dextran derivatives; starch; starch derivatives; and pharmaceutically acceptable salts thereof and wherein the time of the administration of the cysteamine compound, or salt thereof, is an unscheduled time that is not based upon, or determined by, prior experimentation.